Kathleen N. Moore
A5069337573- Ovarian cancer diagnosis and treatment
- PARP inhibition in cancer therapy
- Endometrial and Cervical Cancer Treatments
- Cancer Immunotherapy and Biomarkers
- Lung Cancer Treatments and Mutations
- Cervical Cancer and HPV Research
- Cancer Genomics and Diagnostics
- BRCA gene mutations in cancer
- Intraperitoneal and Appendiceal Malignancies
- Advanced Breast Cancer Therapies
- HER2/EGFR in Cancer Research
- Monoclonal and Polyclonal Antibodies Research
- Radiomics and Machine Learning in Medical Imaging
- Renal cell carcinoma treatment
- Uterine Myomas and Treatments
- PI3K/AKT/mTOR signaling in cancer
- Colorectal Cancer Treatments and Studies
- Cancer Mechanisms and Therapy
- Genetic factors in colorectal cancer
- Cancer-related Molecular Pathways
- Cancer Treatment and Pharmacology
- Endometriosis Research and Treatment
- Angiogenesis and VEGF in Cancer
- Lymphoma Diagnosis and Treatment
- Colorectal and Anal Carcinomas
OU Health
2014-2025
Oklahoma State University Oklahoma City
2016-2025
University of Oklahoma
2016-2025
University of Oklahoma Health Sciences Center
2016-2025
Sarah Cannon
2016-2025
International Fund for Animal Welfare
2011-2025
Oklahoma City University
2016-2025
University of Oklahoma Medical Center
2017-2025
Gynecologic Oncology Group
2009-2025
Christchurch Hospital
2025
Most women with newly diagnosed advanced ovarian cancer have a relapse within 3 years after standard treatment surgery and platinum-based chemotherapy. The benefit of the oral poly(adenosine diphosphate–ribose) polymerase inhibitor olaparib in relapsed disease has been well established, but as maintenance therapy is uncertain.
Data are limited regarding the use of poly(adenosine diphosphate [ADP]-ribose) polymerase inhibitors, such as veliparib, in combination with chemotherapy followed by maintenance initial treatment patients high-grade serous ovarian carcinoma. In an international, phase 3, placebo-controlled trial, we assessed efficacy veliparib added to first-line induction carboplatin and paclitaxel continued monotherapy previously untreated stage III or IV Patients were randomly assigned a 1:1:1 ratio...
Patients with recurrent ovarian carcinoma frequently develop resistance to platinum-based chemotherapy, at which time treatment options become limited.To evaluate the poly(adenosine diphosphate-ribose) polymerase (PARP) inhibitor niraparib combined pembrolizumab in patients carcinoma.The TOPACIO/KEYNOTE-162 (Niraparib Combination With Pembrolizumab Triple-Negative Breast Cancer or Ovarian Cancer) trial, an open-label, single-arm phases 1 and 2 study enrolled women advanced metastatic...
<h3>Importance</h3> Current treatment options for progressive ovarian cancer provide limited benefit, particularly in patients whose disease has become resistant to platinum-based chemotherapy. <h3>Objective</h3> To assess the efficacy and safety of avelumab, an anti–programmed death-ligand 1 agent, a cohort with previously treated recurrent or refractory cancer. <h3>Design, Setting, Participants</h3> In expansion phase 1b, open-label study (JAVELIN Solid Tumor), 125 advanced who had...
Nivolumab was assessed in patients with virus-associated tumors the phase I/II CheckMate 358 trial (ClinicalTrials.gov identifier: NCT02488759). We report on recurrent/metastatic cervical, vaginal, or vulvar cancers.
To provide guidance to clinicians regarding the use of neoadjuvant chemotherapy and interval cytoreduction among women with stage IIIC or IV epithelial ovarian cancer.
In SOLO1/GOG 3004 (ClinicalTrials.gov identifier: NCT01844986), maintenance therapy with the poly(ADP-ribose) polymerase inhibitor olaparib provided a sustained progression-free survival benefit in patients newly diagnosed advanced ovarian cancer and BRCA1 and/or BRCA2 (BRCA) mutation. We report overall (OS) after 7-year follow-up, clinically relevant time point longest follow-up for any first-line setting.This double-blind phase III trial randomly assigned BRCA mutation clinical response to...
To evaluate the addition of humanized monoclonal antiprogrammed death ligand-1 (PD-L1) antibody, atezolizumab, to platinum-based chemotherapy and bevacizumab in newly diagnosed stage III or IV ovarian cancer (OC).This multicenter placebo-controlled double-blind randomized phase trial (ClinicalTrials.gov identifier: NCT03038100) enrolled patients with untreated International Federation Gynecology Obstetrics (FIGO) OC who either had undergone primary cytoreductive surgery macroscopic residual...
ATHENA (ClinicalTrials.gov identifier: NCT03522246) was designed to evaluate rucaparib first-line maintenance treatment in a broad patient population, including those without BRCA1 or BRCA2 (BRCA) mutations other evidence of homologous recombination deficiency (HRD), high-risk clinical characteristics such as residual disease. We report the results from ATHENA-MONO comparison versus placebo. Patients with stage III-IV high-grade ovarian cancer undergoing surgical cytoreduction (R0/complete...
Mirvetuximab soravtansine (MIRV) is an antibody-drug conjugate comprising a folate receptor alpha (FRα)-binding antibody, cleavable linker, and the maytansinoid DM4, potent tubulin-targeting agent. The randomized, open-label, phase III study FORWARD I compared MIRV investigator's choice chemotherapy in patients with platinum-resistant epithelial ovarian cancer (EOC).Eligible 1-3 prior lines of therapy whose tumors were positive for FRα expression randomly assigned, 2 : 1 ratio, to receive (6...
Purpose This phase I expansion cohort study evaluated the safety and clinical activity of mirvetuximab soravtansine (IMGN853), an antibody-drug conjugate consisting a humanized anti-folate receptor alpha (FRα) monoclonal antibody linked to tubulin-disrupting maytansinoid DM4, in population patients with FRα-positive platinum-resistant ovarian cancer. Patients Methods epithelial ovarian, fallopian tube, or primary peritoneal cancer received IMGN853 at 6.0 mg/kg (adjusted ideal body weight)...
We conducted a first-in-human dose-escalation study with the oral FASN inhibitor TVB-2640 to determine maximum tolerated dose (MTD) and recommended phase 2 (RP2D), as monotherapy taxane.This completed open-label outpatient was at 11 sites in United States Kingdom. Patients previously-treated advanced metastatic solid tumors adequate performance status organ function were eligible. administered orally daily until PD. Dose escalation initially followed an accelerated titration design that...
An ASCO provisional clinical opinion offers timely direction to ASCO's membership following publication or presentation of potentially practice-changing data from major studies. This addresses the appropriate use tumor genomic testing in patients with metastatic advanced solid tumors.An increasing number therapies are approved treat cancers harboring specific biomarkers. However, there is a lack clarity as when sequencing should be ordered, what type assays performed, and how interpret...
Immunotherapy and chemotherapy combinations have shown activity in endometrial cancer, with greater benefit mismatch repair (MMR)-deficient (dMMR) than MMR-proficient (pMMR) disease. Adding a poly(ADP-ribose) polymerase inhibitor may improve outcomes, especially pMMR
Mirvetuximab soravtansine-gynx (MIRV), a first-in-class antibody-drug conjugate targeting folate receptor α (FRα), is approved for the treatment of platinum-resistant ovarian cancer in United States.We conducted phase 3, global, confirmatory, open-label, randomized, controlled trial to compare efficacy and safety MIRV with investigator's choice chemotherapy platinum-resistant, high-grade serous cancer. Participants who had previously received one three lines therapy high FRα tumor expression...